Alnylam RNAi IP Upheld in European Opposition Proceedings | GenomeWeb

Alnylam Pharmaceuticals said this week that its Tuschl II patent has been fully upheld by the European Patent Office in opposition proceedings.

The patent, EP 1407044, generally relates to compositions, methods, and uses of siRNAs capable of triggering an RNAi effect. Alnylam said that opponents to the patent included Merck subsidiary Sirna Therapeutics, Silence Therapeutics, Pfizer, and BASF.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.